Masitinib-loaded poly(lactic-co-glycolic acid) nanoparticles reinstate lysosomal acidification and drive immunomodulation in Alzheimer's disease.
Alzheimer's disease (AD) poses a formidable therapeutic challenge due to its intricate pathological mechanisms and the blood-brain barrier (BBB). Via transcriptomic analyses and experimental validation, we identify that a malignant neuro-immune pathological cycle, driven by neuronal lysosomal acidification dysfunction...